All In Biotech

Drug Trial Radar · NCT03745287

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

63

Actual

Start

Nov 27, 2018

Primary completion

Jul 7, 2025

Study completion Jul 7, 2025

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
Collaborators
CRISPR Therapeutics
First posted
Nov 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participants with severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

Conditions

  • Sickle Cell Disease
  • Hematological Diseases
  • Hemoglobinopathies

Interventions

  • Exa-celBiological

    Administered by IV infusion following myeloablative conditioning with busulfan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel InfusionTime frame: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
  2. Percentage of Participants Who Achieve Neutrophil EngraftmentTime frame: Up to 24 months post exa-cel infusion.
  3. Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil EngraftmentTime frame: Up to 24 months post exa-cel infusion.
  4. Time to Platelet Engraftment for Participants Who Achieve Platelet EngraftmentTime frame: From Exa-cel infusion up to 2 years after exa-cel infusion
  5. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From receiving exa-cel infusion up to 2 years
  6. Transplant-related Mortality (TRM) Within 100 Days After Exa-cel InfusionTime frame: Within 100 days after exa-cel infusion
  7. Transplant-related Mortality Within 12 Months Post Exa-cel InfusionTime frame: Within 12 months post exa-cel infusion
  8. All-cause MortalityTime frame: From exa-cel infusion up to 2 years

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Lucile Packard Children's Hospital of Stanford University

    Palo Alto, California

  • Ann & Robert Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Illinois at Chicago Hospitals and Health Systems

    Chicago, Illinois

  • Columbia University Medical Center (21+ years)

    New York, New York

  • Columbia University Medical Center (≤21 years)

    New York, New York

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers

    Nashville, Tennessee

  • Methodist Children's Hospital/Texas Transplant Institute

    San Antonio, Texas

  • Hopital Universitaire des Enfants Reine Fabiola (HUDERF)

    Brussels, Belgium

  • The Hospital for Sick Children

    Toronto, Canada

  • Hopital Necker Enfants Malades

    Paris, France

  • University Hospital Duesseldorf

    Düsseldorf, Germany

  • Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Paediatric Haemotology, Oncology and Stem Cell Transplantation

    Regensburg, Germany

  • Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS

    Rome, Italy

  • Imperial College Healthcare NHS Trust, Hammersmith Hospital

    London, United Kingdom

  • Royal London and St Bartholomew's Hospital, Pathology and Pharmacy Building

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.